Late effects of early growth hormone treatment in Down syndrome.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

The aim of this study was to investigate late effects of early GH treatment on growth and psychomotor development in the DS subjects from the previous trial.

The Bruininks-Oseretsky Test of Motor Proficiency, Second edition (BOT-2), was used to assess general motor ability.

Who Took Part

According to the abstract, 15 adolescents were involved.

PubMed indexes the participants as teenagers and young adults, both men and women.

Fifteen other subjects with DS (6 F) were included as controls in anthropometric analyses.

Cognitive function was assessed with the Leiter International Performance Scale-Revised (Leiter-R) and selected subtests of the Wechsler Intelligence Scale for Children, Third edition (WISC-III).

How the Study Was Run

Twelve of 15 adolescents with DS (3 F) from the GH group and 10 of 15 controls (5 F) participated in this follow-up study.

What Was Measured

Topics PubMed links to this paper include Cognition, Down Syndrome, Growth, Head, Human Growth Hormone, Intelligence Tests and Motor Activity.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 15 adolescents.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Acta paediatrica (Oslo, Norway : 1992)), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.